Intravenous inotropic agents in the intensive therapy unit: Do they really make a difference?

Cristina Opasich, Alessandra Russo, Renato Mingrone, Mara Zambelli, Luigi Tavazzi

Research output: Contribution to journalArticle

Abstract

Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only midly elevated ventricular filling pressures. The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed. (C) 2000 European Society of Cardiology.

Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalEuropean Journal of Heart Failure
Volume2
Issue number1
DOIs
Publication statusPublished - Mar 1 2000

Fingerprint

Ventricular Pressure
Cardiac Output
Heart Failure
Hemodynamics
Oxygen
Therapeutics

Keywords

  • Heart failure
  • Intensive therapy
  • Intravenous inotropics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Intravenous inotropic agents in the intensive therapy unit : Do they really make a difference? / Opasich, Cristina; Russo, Alessandra; Mingrone, Renato; Zambelli, Mara; Tavazzi, Luigi.

In: European Journal of Heart Failure, Vol. 2, No. 1, 01.03.2000, p. 7-11.

Research output: Contribution to journalArticle

Opasich, Cristina ; Russo, Alessandra ; Mingrone, Renato ; Zambelli, Mara ; Tavazzi, Luigi. / Intravenous inotropic agents in the intensive therapy unit : Do they really make a difference?. In: European Journal of Heart Failure. 2000 ; Vol. 2, No. 1. pp. 7-11.
@article{9df48b651308491eaee0420cdd1d64d2,
title = "Intravenous inotropic agents in the intensive therapy unit: Do they really make a difference?",
abstract = "Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only midly elevated ventricular filling pressures. The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed. (C) 2000 European Society of Cardiology.",
keywords = "Heart failure, Intensive therapy, Intravenous inotropics",
author = "Cristina Opasich and Alessandra Russo and Renato Mingrone and Mara Zambelli and Luigi Tavazzi",
year = "2000",
month = "3",
day = "1",
doi = "10.1016/S1388-9842(99)00061-6",
language = "English",
volume = "2",
pages = "7--11",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "1",

}

TY - JOUR

T1 - Intravenous inotropic agents in the intensive therapy unit

T2 - Do they really make a difference?

AU - Opasich, Cristina

AU - Russo, Alessandra

AU - Mingrone, Renato

AU - Zambelli, Mara

AU - Tavazzi, Luigi

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only midly elevated ventricular filling pressures. The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed. (C) 2000 European Society of Cardiology.

AB - Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only midly elevated ventricular filling pressures. The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed. (C) 2000 European Society of Cardiology.

KW - Heart failure

KW - Intensive therapy

KW - Intravenous inotropics

UR - http://www.scopus.com/inward/record.url?scp=0034039196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034039196&partnerID=8YFLogxK

U2 - 10.1016/S1388-9842(99)00061-6

DO - 10.1016/S1388-9842(99)00061-6

M3 - Article

C2 - 10742697

AN - SCOPUS:0034039196

VL - 2

SP - 7

EP - 11

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -